Administration of montelukast or placebo
Pre-clinicalWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Exercise-Induced Bronchospasm
Conditions
Exercise-Induced Bronchospasm
Trial Timeline
Oct 1, 2006 → —
NCT ID
NCT00375232About Administration of montelukast or placebo
Administration of montelukast or placebo is a pre-clinical stage product being developed by Merck for Exercise-Induced Bronchospasm. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00375232. Target conditions include Exercise-Induced Bronchospasm.
What happened to similar drugs?
2 of 8 similar drugs in Exercise-Induced Bronchospasm were approved
Approved (2) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00375232 | Pre-clinical | Withdrawn |
Competing Products
10 competing products in Exercise-Induced Bronchospasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levalbuterol tartrate HFA MDI + Placebo | Sumitomo Pharma | Phase 3 | 40 |
| Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhaler | AstraZeneca | Phase 3 | 40 |
| Benralizumab | AstraZeneca | Phase 3 | 36 |
| Ambrisentan | Gilead Sciences | Approved | 43 |
| Combination DSCG and Reproterol | Sanofi | Phase 2 | 35 |
| Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified) | Organon | Approved | 37 |
| Comparator: Montelukast + Comparator: Placebo | Organon | Phase 3 | 34 |
| Comparator: Montelukast + Comparator: Placebo | Organon | Phase 3 | 34 |
| montelukast sodium + Comparator: placebo (unspecified) | Organon | Phase 1 | 23 |
| Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol) | Organon | Phase 3 | 34 |